ProMIS Neurosciences Inc. ((PMN)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ProMIS Neurosciences Inc. is conducting a Phase 1b clinical study titled ‘A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer’s Disease.’ The study aims to evaluate the safety and preliminary efficacy of PMN310, a monoclonal antibody, in patients with early Alzheimer’s disease.
The intervention being tested is PMN310, a humanized immunoglobulin G1 (IgG1) monoclonal antibody, administered via intravenous infusion. The study includes three cohorts with escalating doses of 350 mg, 700 mg, and 1400 mg, compared against a placebo.
This interventional study is randomized and follows a sequential intervention model with double masking for both participants and investigators. The primary purpose is treatment-focused, aiming to assess the drug’s impact on early Alzheimer’s symptoms.
The study began on December 16, 2024, with the latest update submitted on September 3, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The ongoing study could significantly impact ProMIS Neurosciences’ stock performance, as positive results may boost investor confidence and market valuation. In the competitive Alzheimer’s treatment landscape, advancements in PMN310 could position ProMIS as a key player.
The study is currently recruiting, with further details available on the ClinicalTrials portal.